FDA warns of rare blindness risk from GLP-1 weight loss drugs
Audio narration · Coming soon
The FDA has issued a warning about a rare eye condition that can cause blindness linked to GLP-1 weight loss medications. The agency now requires all GLP-1 drugs to carry warning labels informing patients of this potential risk.
Why this matters
PRISM scored this story 55/100 for interest.
Originally published by gnews